liu.seSearch for publications in DiVA
Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Differential lipid profile and hormonal response in type 2 diabetes by exogenous insulin aspart versus the insulin secretagogue repaglinide, at the same glycemic control
Linköpings universitet, Institutionen för klinisk och experimentell medicin, Cellbiologi. Linköpings universitet, Hälsouniversitetet. Östergötlands Läns Landsting, Närsjukvården i centrala Östergötland, Akutkliniken.
Linköpings universitet, Institutionen för medicin och hälsa, Internmedicin. Linköpings universitet, Hälsouniversitetet. Östergötlands Läns Landsting, Medicincentrum, Endokrin- och magtarmmedicinska kliniken US.
Borensberg Health Centre, Linköping.
Linköpings universitet, Institutionen för klinisk och experimentell medicin, Cellbiologi. Linköpings universitet, Hälsouniversitetet.
Vise andre og tillknytning
2009 (engelsk)Inngår i: Acta Diabetologica, ISSN 0940-5429, E-ISSN 1432-5233, Vol. 46, nr 1, s. 35-42Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Our aim was to study, at the same glycemic control, how treatment with either the insulin secretagogue repaglinide or exogenous insulin aspart affects endogenous insulin secretion, plasma insulin and IAPP (islet amyloid polypeptide) levels, GH-IGF (growth hormone-insulin-like growth factor) axis and plasma lipoprotein concentrations in patients with type 2 diabetes. Five patients, age 65.0 +/- A 4.1 years (mean +/- A SE), body weight 82.5 +/- A 5.0 kg, BMI (body mass index) 27.7 +/- A 1.5 kg/m(2) were treated for 10 weeks with repaglinide or insulin aspart in a randomized, cross-over study. At the end of each treatment a 24-h metabolic profile was performed. Blood glucose, C-peptide, free human insulin, free total (human and analogue) insulin, proinsulin, IAPP, IGF-I, IGFBP-1 (IGF binding protein-1), GHBP (growth hormone binding protein) and plasma lipoprotein concentrations were measured. Similar 24-h blood glucose profiles were obtained with repaglinide and insulin aspart treatment. During the repaglinide treatment, the meal related peaks of C-peptide and free human insulin were about twofold higher than during treatment with insulin aspart. Proinsulin, GHBP were higher and IAPP levels tended to be higher during repaglinide compared to insulin aspart. Postprandial plasma total cholesterol, triglycerides and apolipoprotein B concentrations were higher on repaglinide than on insulin aspart treatment. Our results show that, at the same glycemic control, treatment with exogenous insulin aspart in comparison with the insulin secretagogue repaglinide result in a lower endogenous insulin secretion, and a tendency towards a less atherogenic postprandial lipid profile.

sted, utgiver, år, opplag, sider
2009. Vol. 46, nr 1, s. 35-42
Emneord [en]
Insulin secretagogue, Insulin-like growth factor, Lipoprotein
HSV kategori
Identifikatorer
URN: urn:nbn:se:liu:diva-16891DOI: 10.1007/s00592-008-0055-6ISI: 000263001000005OAI: oai:DiVA.org:liu-16891DiVA, id: diva2:174438
Merknad

The original publication is available at www.springerlink.com: Ioana Simona Chisalita, Torbjörn Lindström, Pär Eson Jennersjö, Johan Paulsson, Gunilla Westermark, Anders Olsson and Hans Arnqvist, Differential lipid profile and hormonal response in type 2 diabetes by exogenous insulin aspart versus the insulin secretagogue repaglinide, at the same glycemic control, 2009, ACTA DIABETOLOGICA, (46), 1, 35-42. http://dx.doi.org/10.1007/s00592-008-0055-6 Copyright: Springer -- Verlag http://www.springerlink.com/

Tilgjengelig fra: 2009-02-26 Laget: 2009-02-20 Sist oppdatert: 2017-12-13bibliografisk kontrollert

Open Access i DiVA

fulltekst(371 kB)1144 nedlastinger
Filinformasjon
Fil FULLTEXT01.pdfFilstørrelse 371 kBChecksum SHA-512
bd63406919e6126aef9e02b560e072e703fc970e58c2c633ecbb39dcb4d69a5032c98460c5e0a8af3d63ace2f93f26aaf853ffa97fd07582865ca6348bc93026
Type fulltextMimetype application/pdf

Andre lenker

Forlagets fulltekst

Personposter BETA

Chisalita, Simona IoanaLindström, TorbjörnPaulsson, JohanWestermark, GunillaOlsson, AndersArnqvist, Hans

Søk i DiVA

Av forfatter/redaktør
Chisalita, Simona IoanaLindström, TorbjörnPaulsson, JohanWestermark, GunillaOlsson, AndersArnqvist, Hans
Av organisasjonen
I samme tidsskrift
Acta Diabetologica

Søk utenfor DiVA

GoogleGoogle Scholar
Totalt: 1144 nedlastinger
Antall nedlastinger er summen av alle nedlastinger av alle fulltekster. Det kan for eksempel være tidligere versjoner som er ikke lenger tilgjengelige

doi
urn-nbn

Altmetric

doi
urn-nbn
Totalt: 569 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf